Robot-aided thoracoscopic thymectomy for early-stage thymoma: A multicenter European study

Minimally invasive thymectomy for stage I to stage II thymoma has been suggested in recent years and considered technically feasible. However, because of the lack of data on long-term results, controversies still exist on surgical access indication. We sought to evaluate the results after robot-assi...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of thoracic and cardiovascular surgery Vol. 144; no. 5; pp. 1125 - 1132
Main Authors Marulli, Giuseppe, Rea, Federico, Melfi, Franca, Schmid, Thomas A., Ismail, Mahmoud, Fanucchi, Olivia, Augustin, Florian, Swierzy, Marc, Di Chiara, Francesco, Mussi, Alfredo, Rueckert, Jens C.
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 01.11.2012
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Minimally invasive thymectomy for stage I to stage II thymoma has been suggested in recent years and considered technically feasible. However, because of the lack of data on long-term results, controversies still exist on surgical access indication. We sought to evaluate the results after robot-assisted thoracoscopic thymectomy in early-stage thymoma. Data were collected from 4 European centers. Between 2002 and 2011, 79 patients (38 men and 41 women; median age, 57 years) with early-stage thymoma were operated by left-sided (82.4%), right-sided (12.6%), or bilateral (5%) robotic thoracoscopic approach. Forty-five patients (57%) had associated myasthenia gravis. Average operative time was 155 minutes (range, 70-320 minutes). One patient needed open conversion, in 1 patient a standard thoracoscopy was performed after robotic system breakdown, and in 5 patients an additional access was required. No vascular and nervous injuries were recorded, and no perioperative mortality occurred. Ten patients (12.7%) had postoperative complications. Median hospital stay was 3 days (range, 2-15 days). Median diameter of tumor resected was 3 cm (range, 1-12 cm), and Masaoka stage was stage I in 30 patients (38%) and stage II in 49 patients (62%). At a median follow-up of 40 months, 74 patients were alive and 5 had died (4 patients from nonthymoma-related causes and 1 from a diffuse intrathoracic recurrence), with a 5-year survival rate of 90%. Our data indicate that robot-enhanced thoracoscopic thymectomy for early-stage thymoma is a technically sound and safe procedure with a low complication rate and a short hospital stay. Oncologic outcome seems good, but a longer follow-up is needed to consider this as a standard approach definitively.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-5223
1097-685X
1097-685X
DOI:10.1016/j.jtcvs.2012.07.082